ArticleApplied microbiology and biotechnology2025
Foot-and-mouth disease vaccine with insertion of a 24-amino acid VP1 G-H loop epitope of the Cathay virus provides broad antigenic coverage.
Article in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- VP1 region-based molecular characterization of foot-and-mouth disease virus serotype O from clinical cases in Haryana, India.BMC veterinary research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Vaccination with inactivated whole-virus vaccines remains the most effective measure for controlling foot-and-mouth disease virus (FMDV) transmission and disease outbreaks. However, the existing type O FMDV vaccines show suboptimal efficacy and antigenic mismatch to the circulating Cathay viruses in China, thus requiring the development of a new vaccine. The VP1 G-H loop is a hypervariable region and plays a pivotal role in the protective immunity induced by FMDV vaccines. Here, we engineered four recombinant FMDVs with insertions of a 20-amino acid (aa) or a 24-aa G-H loop epitope of a prevalent Cathay strain upstream or downstream of the RGD (Arg-Gly-Asp) motif. The recombinant viruses with insertions upstream of the RGD motif retained parental virus-like plaque morphology and replication kinetics and maintained genetic stability even after 20 serial passages. In contrast, the downstream insertion variants exhibited small plaque morphology, reduced growth capacity, and acquired 1 or 2 aa mutations in the capsid proteins by passage 20. The parental virus vaccine induced high titer protective mean neutralizing antibodies (> 1:128) against viruses of the Mya98, PanAsia, and Ind-2001 lineages but failed to elicit protective mean neutralizing antibodies (< 1:22) to the Cathay virus after 28 days vaccination (dpv) in pigs. In contrast, vaccines containing upstream insertions both exhibited protective immune response to viruses of four lineages. Especially, pigs vaccinated with vaccine containing a 24-aa insertion produced significantly higher mean neutralizing antibody against the Cathay virus (p < 0.01), compared to those vaccinated with vaccine having a 20-aa insertion, indicating that the recombinant virus with 24-aa insertion has great potential as a vaccine candidate for serotype O FMD control. This study provides crucial insights for designing FMDV vaccines in the future. KEY POINTS: • This study firstly reported that FMDV can tolerate a 24-aa insertion in the VP1 G-H loop • The G-H loop insertions at different sites of FMDV VP1 have different impacts on viral replication capacity • Vaccines containing the G-H loop insertions can induce markedly high neutralizing antibodies to the Cathay virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.